Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-25-028226
Filing Date
2025-04-02
Accepted
2025-04-02 18:20:52
Documents
1
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT ownership.html 4  
1 OWNERSHIP DOCUMENT ownership.xml 4 19677
  Complete submission text file 0001213900-25-028226.txt   21179
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 300 E 93RD STREET, #20-B NEW YORK NY 10128
Business Address
SETH SANDESH (Reporting) CIK: 0001566175 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36374 | Film No.: 25806693